Niche-3, CABINET, and Other GI Oncology Updates From ESMO 2024
By Benjamin Weinberg, MD, FACP - Last Updated: March 19, 2025Benjamin Weinberg, MD, FACP, Associate Professor of Medicine at Lombardi Comprehensive Cancer Center, provides a recap of all of the gastrointestinal oncology data and studies of practice-changing potential the were presented at the ESMO Congress 2024.
Advertisement
Included in his round-up are notes on Niche-3, CABINET, CodeBreaK 101, TOPGEAR, and many others.
Advertisement
Related Posts
A multivariate analysis revealed HER2-targeted therapy to be an independent prognostic factor for OS.
Dr. Kim discusses how ctDNA compares to traditional imaging and how findings can affect adjuvant treatment decisions for BTC.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
Among 16 patients with confirmed recurrence, ctDNA accurately identified recurrence in 15 patients.
Dr. Pant offered insights on the key findings of zanidatamab's efficacy and safety in HER2-positive BTC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.